Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

NAD+ (nicotinamide adenine dinucleotide) fuels cellular energy production, while GLP-1 receptor agonists reduce hunger and improve glucose control—two distinct mechanisms that some patients ask about combining. Current clinical evidence shows no direct contraindication, but the interaction profile remains understudied in weight loss populations, making informed prescribing essential.

How NAD+ and GLP-1 Medications Work on Different Pathways

NAD+ exists in two forms: NAD+ (oxidized) and NADH (reduced), cycling through energy-producing reactions in every cell. It powers the mitochondrial electron transport chain, ATP synthesis, and sirtuin activation—processes that decline with age and metabolic stress. GLP-1 receptor agonists like semaglutide and tirzepatide, by contrast, bind to intestinal and neuronal GLP-1 receptors to slow gastric emptying, increase insulin secretion, and activate satiety centers in the brain. Because these medications operate on separate molecular systems, a NAD+ booster and a GLP-1 compound do not directly compete for the same binding sites or enzymatic pathways.

PlexusDx GLP-Squared combines semaglutide and tirzepatide—a dual-GLP-1/GIP approach—because both activate complementary weight loss mechanisms within the same receptor family. Adding NAD+ introduces a third, non-overlapping system: mitochondrial metabolism. Theoretically, enhancing cellular energy availability while suppressing appetite could create synergistic metabolic support, but human clinical trials testing this specific combination remain scarce. Your prescribing clinician must weigh the potential benefit against unknown interaction risks when initiating dual therapies.

NAD+ Supplement Forms and Bioavailability Concerns

Common NAD+ precursor supplements include nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and direct NAD+ oral formulations. Oral NAD+ has poor intestinal absorption because it is too large and charged to cross epithelial barriers; most NAD+ supplement research uses NR or NMN, which convert to NAD+ inside cells. Dosing varies widely (250 mg to 1,000 mg daily in trials), and bioavailability depends on individual genetics, gut microbiota composition, and concurrent medications. If a patient takes a GLP-1 agonist, which slows gastric emptying and reduces caloric absorption, NAD+ precursor absorption may be further impaired—meaning the supplement dose might reach target tissue at lower-than-expected concentrations.

PlexusDx offers the Precision Peptide Genetic Test, which maps genetic variants affecting NAD+-related pathways and mitochondrial function. Carriers of certain alleles in SIRT1, PARP1, or mitochondrial genes may benefit more from NAD+ supplementation, while others show minimal response. A personalized genetic assessment helps clinicians decide whether adding NAD+ to a GLP-1 regimen makes individual sense, rather than assuming a one-size-fits-all approach.

Safety Profile of Combining NAD+ With GLP-1 Therapy

No published adverse drug interaction study specifically examines NAD+ precursors with semaglutide, tirzepatide, or dual GLP-1/GIP compounds. The American Society of Clinical Pharmacology reports no direct receptor antagonism, enzymatic inhibition, or renal/hepatic pathway overlap that would predict a clinically significant interaction. However, indirect effects are possible: NAD+ boosters may increase mitochondrial ATP production and metabolic rate, potentially amplifying appetite suppression beyond GLP-1 monotherapy and risking undereating or nutrient deficiency. Additionally, NAD+-dependent sirtuins influence insulin sensitivity and glucose metabolism; combined with GLP-1's own insulin-enhancing effects, hypoglycemia risk could theoretically increase in diabetic patients.

PlexusDx clinicians monitor combined therapies with baseline and serial bloodwork, including fasting glucose, HbA1c, liver function tests, and micronutrient panels (B12, folate, iron). Patients initiating NAD+ and GLP-1 together must report energy levels, appetite changes, nausea, and any dizziness or shakiness suggesting low blood sugar. While the dual approach is not contraindicated, it requires heightened clinical oversight and should only be pursued under the care of a physician experienced in both NAD+ biology and GLP-1 pharmacology.

PlexusDx Personalized Approach to GLP-1 and Metabolic Support

PlexusDx GLP-Squared injection (starting at $249/mo) delivers compounded semaglutide and tirzepatide in a single formulation, optimizing dual-pathway weight loss without requiring patients to manage two separate medications or needles. For patients interested in metabolic synergy, PlexusDx offers the Precision Peptide Genetic Test ($99 add-on after first month of treatment), which analyzes 49 peptides across 14 metabolic pathways—including NAD+-dependent processes, mitochondrial function genes, and appetite-control variants like GLP1R rs6923761 and MC4R rs17782313. Results inform whether NAD+ supplementation aligns with your genetic profile, and PlexusDx clinicians integrate that data into your personalized treatment plan.

All PlexusDx medications come from licensed 503A compounding pharmacies, require no insurance, and are HSA/FSA eligible, making precision weight loss accessible across all 50 states. If you are considering combining NAD+ with GLP-1 therapy, schedule a consultation with a PlexusDx clinician who can review your medical history, genetics, and goals to design a safe, evidence-informed regimen tailored specifically to you.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Glp Squared starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take NAD+ supplements while using PlexusDx semaglutide or tirzepatide?

No direct contraindication exists between NAD+ precursors and GLP-1 agonists; they work on separate pathways. However, combined therapies require medical oversight because GLP-1's effect on gastric emptying may reduce NAD+ supplement absorption, and both agents influence glucose metabolism. PlexusDx clinicians will evaluate your individual case and monitor your response with regular bloodwork.

Does adding NAD+ to GLP-1 therapy improve weight loss results?

No clinical trial has directly compared GLP-1 alone versus GLP-1 plus NAD+ supplementation for weight loss. NAD+ boosters may enhance mitochondrial energy and metabolic rate, potentially amplifying appetite suppression, but evidence remains theoretical. Your PlexusDx clinician can discuss whether NAD+ aligns with your genetic profile using the Precision Peptide Genetic Test and adjust your GLP-1 dose accordingly.

What is GLP-Squared, and how does it relate to NAD+ therapy?

GLP-Squared is a dual-compound injection combining semaglutide and tirzepatide, engaging both GLP-1 and GIP receptors for enhanced weight loss. Starting at $249/mo, it simplifies medication management. If you want to add NAD+ metabolic support, GLP-Squared provides a solid foundation, and PlexusDx testing can confirm whether NAD+ supplementation matches your genetic risk and benefit profile.

Could combining NAD+ and GLP-1 cause low blood sugar?

Yes, there is a theoretical risk: NAD+-dependent sirtuins improve insulin sensitivity, and GLP-1 agonists boost insulin secretion. In diabetic patients on medications, this could lower blood glucose unexpectedly. PlexusDx clinicians monitor glucose levels closely if you combine these therapies and adjust doses as needed to maintain safety.

How does the Precision Peptide Genetic Test help with NAD+ and GLP-1 choices?

The test analyzes 150+ genetic insights across 49 peptides and 14 pathways, including NAD+-related genes like SIRT1 and mitochondrial enzymes. It identifies whether your genetic makeup predicts strong NAD+ response, which helps PlexusDx clinicians decide if adding NAD+ to your GLP-1 regimen makes personalized sense, available for $99 after your first month of treatment.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves